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Neuroﬁbromatosis  type 1 (NF1)  is  an  autosomal  dominant  disorder,  associated  with  a variable  clini-
cal  phenotype  including  café-au-lait  spots,  intertriginous  freckling,  Lisch  nodules,  neuroﬁbromas,  optic
pathway  gliomas  and  distinctive  bony  lesions.  NF1  is caused  by  a  mutation  in  the  NF1  gene,  which
codes  for neuroﬁbromin,  a large  protein  involved  in  the MAPK-  and  the  mTOR-pathway  through  RAS-RAF
signalling.
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NF1  is  a known  tumour  predisposition  syndrome,  associated  with  different  tumours  of the nervous  system
including  low  grade  gliomas  (LGGs)  in  the  paediatric  population.  The  focus  of this  review  is  on  grade  I
pilocytic  astrocytomas  (PAs),  the  most  commonly  observed  histologic  subtype  of low  grade  gliomas  in
NF1.  Clinically,  these  PAs have  a better  prognosis  and  show  different  localisation  patterns  than  their
sporadic  counterparts,  which  are  most  commonly  associated  with  a KIAA1549:BRAF  fusion.
In  this  review,  possible  mechanisms  of  tumourigenesis  in  LGGs  with  and  without  NF1  will  be  discussed,
including  the  contribution  of  different  signalling  pathways  and tumour  microenvironment.  Furthermore
we will  discuss  how  increased  understanding  of tumourigenesis  may  lead to  new  potential  targets  for
treatment.
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Low grade gliomas are the most commonly found tumours of
the central nervous system in the paediatric population, both in©  2016  The  Author(s).  P
. Introduction: neuroﬁbromatosis type 1
Neuroﬁbromatosis type 1 (NF1) or von Recklinghausen’s disease
s an autosomal dominant disorder with a worldwide incidence of
 per 2500–3000 individuals. It is characterized by the presence
f café-au-lait spots, intertriginous freckling, Lisch nodules, neu-
oﬁbromas, optic pathway gliomas and distinctive bony lesions.
ther features include malignant peripheral nerve sheath tumours
MPNSTs), neurocognitive defects, epilepsy and cardiovascular
bnormalities (Williams et al., 2009). NF1 is caused by a muta-
ion in the NF1 gene, located on chromosome 17q11.2 (Wallace
t al., 1990; Viskochil et al., 1990). NF1 is a familial disorder with a
endelian inheritance pattern, but approximately half of the NF1
ases are caused by newly appearing mutations (Messiaen et al.,
000).
Although NF1 is an autosomal dominant disorder with 100%
enetrance, there is a great variance in clinical presentation with
elatively minor contribution of the nature of the NF1 mutation to
isease expression. The only genotype-phenotype correlation that
as been well established is that patients with an NF1 microdele-
ion have a more severe phenotype with higher incidence of
euroﬁbromas and MPSNTs, a lower mean IQ, and distinct facial
eatures (De Raedt et al., 2003; Wu  et al., 1997). Other explana-
ions for the great inter- and intrafamilial variation in NF1 may be
nvironmental factors or the impact of modiﬁer genes, such as mis-
atch repair genes. Cell lines with mutations in these genes show
n increased number of somatic mutations of the NF1 gene, which
ay  possibly lead to increased symptom load in patients carrying
hese mutations (Pasmant et al., 2012; Wang et al., 2003).
The NF1 gene codes for neuroﬁbromin, a cytoplasmatic, 2818
mino acids containing protein. Neuroﬁbromin is widely expressed
hroughout different tissues including neurons and astrocytes of
he central nervous system, where it is believed to be involved
n cortical development and astrocyte growth (Gutmann, 2002;
utmann et al., 1991; Andersen et al., 1993; Zhu et al., 2001).
Neuroﬁbromin is critically involved in different cellular
rocesses through inﬂuencing signalling pathways. Firstly, neuroﬁ-
romin promotes the conversion of ATP to cyclic AMP, where an
bsence of NF1 gene activity decreases c-AMP levels (Tong et al.,
002). Through this pathway, neuroﬁbromin has a positive rela-
ionship with learning, life span and stress resistance in Drosophilia
odels (Tong et al., 2007; Guo et al., 2000) (Fig. 1).
Furthermore, neuroﬁbromin acts as a negative regulator of RAS
y functioning as a GTPase-activating protein (GAP), increasing the
onversion of GTP-bound RAS to its GDP-bound form (Andersen
t al., 1993; Basu et al., 1992). Loss of neuroﬁbromin increases RAS
ctivity and induces downstream activity of the MEK-ERK (MAPK,
itogen activated protein kinase) pathway as well as the PI3K-
kt-mTOR (mammalian target of rapamycin) pathway (Sandsmark
t al., 2007; Banerjee et al., 2011a; Johannessen et al., 2005).
hrough these signalling pathways, neuroﬁbromin functions as a
egative regulator of cell growth and proliferation (Fig. 1).hed  by  Elsevier  Ireland  Ltd. This  is an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
2. NF1 and malignancies
NF1 is associated with an increased risk of malignancies, both
nervous-system and non-nervous system related. Non-nervous
system tumours include gastro-intestinal stromal tumours, duo-
denal carcinoids and phaechromocytomas as well as breast cancer
and rhabdomyosarcomas. Nervous-system malignancies are both
located in the central and peripheral nervous system. Malignant
tumours of the peripheral nervous system include MPNSTs, most
commonly arising from plexiform neuroﬁbromas, and more rarely
neuroblastomas (Brems et al., 2009). The lifetime risk of developing
MPNSTs is 8–13% for NF1 patients and these tumours usually occur
in adulthood (Evans et al., 2002).
The most common central-nervous system tumours in NF1 are
low grade gliomas, with the optic pathway glioma being a hallmark
lesion (Szudek et al., 2000). Higher grade gliomas are also more
frequently found in NF1, but are almost only observed during adult
life, while low grade gliomas are far more common in the paediatric
population (Gutmann et al., 2002).
In most NF1-related malignancies, including astrocytomas,
MPNSTs and neuroblastomas, biallelic inactivation of NF1 gene
function is found in the affected cells (Upadhyaya et al., 2008;
Origone et al., 2003; Gutmann et al., 2000). Somatic inactivation of
the still functioning NF1 allele is believed to be required for tumour
formation. This ‘second hit’ creates an absence of neuroﬁbromin
in affected cells, diminishing its normal functions, including those
of controlling cell growth and proliferation. With this role of the
NF1 gene as a tumour suppressor, it is not surprising that somatic
mutations of the NF1 gene are also commonly found in different
non NF1-associated tumours (Li et al., 1992).
In aggressive NF1-related tumours, such as MPNSTs and high
grade gliomas additional mutations are found, such as mutations
in TP53 and CDKN2A (Nielsen et al., 1999; Legius et al., 1994). These
mutations may  be important for the malignant transformation of
relatively benign neuroﬁbromas and astrocytomas, as is supported
by mouse models where mice mutant for NF1 and Tp53 develop
high grade gliomas (Reilly et al., 2004; Zhu et al., 2005a). CDKN2A
(p16) and p53 are important in regulating cell cycle control by
inhibiting cell cycle progression. Their activation is partially reg-
ulated by Ras through the Ink4/ARF locus, which encodes p16INK4A
and p19ARF. p16INK4A regulates the retinoblastoma (RB) protein,
while p19ARF activates p53 by diminshed inhibition of Mdm2
(Fig. 1) (Lin and Lowe, 2001).
3. NF1 and low grade gliomas
3.1. Phenotypechildren with and without NF1. While these low grade gliomas
have an excellent prognosis after gross total resection, they can
32 J. Helfferich et al. / Critical Reviews in Oncology/Hematology 104 (2016) 30–41
Fig. 1. NF1 regulates cell proliferation, differentiation, survival and growth through the MAPK- and mTOR pathway and cAMP signalling. It functions as a GAP  for RAS, thereby
working as a negative regulator of RAS-phosphorylation. Loss of NF1 therefore activates RAS and downstream signalling pathways and inhibits cAMP signalling. RAS also
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aontrols the p16 and p53 cell cycle control pathways through Ink4/ARF. Diminished
RAF  alterations and mutations also activate the MAPK and mTOR-pathway; mTOR
heir  targets are also shown in the ﬁgure. (FTI: Farnestyltransferase inhibitors).
e associated with signiﬁcant morbidity and occasional mortal-
ty. For example, children with optic tract gliomas may  have loss
f visual acuity and show endocrine abnormalities such as dien-
ephalic syndrome and precocious puberty. Surgery is not the ﬁrst
hoice of treatment in NF1-associated optic gliomas, due to inac-
essible tumour location and the relatively benign behaviour as
ell as the neurologic detoriation associated with resection of these
umours. Therefore other treatment forms such as chemotherapy
r, in exceptional situations, radiotherapy are needed. The latter is
owever less desirable as it is associated with the development of
oya-Moya disease in NF1 patients.
Due to tumour location and therapeutic intervention, there is an
levated risk for cognitive and behavioural impairment in children
ith low grade gliomas (Ris et al., 2008; Armstrong et al., 2011). This
ide effect is rather undesirable in NF1 patients, who are already
rone to cognitive impairment.
In general, low grade gliomas form a group of WHO  grade I and
rade II brain tumours which are classiﬁed based on malignancy
rade and the presumed cell of origin. The most common sub-
ypes are WHO  grade I pilocytic astrocytomas (PAs) and grade II
ilomyxoid and diffuse astrocytomas (Louis et al., 2007).
PAs are histologically characterized by GFAP-staining in the
ell cytoplasm and the presence of Rosenthal ﬁbers, but show
reat histological variability, sometimes making deﬁnite charac-
erization difﬁcult. Pilomyxoid astrocytomas exhibit histological
imilarities with PAs and are considered grade II variant of PAs
n the WHO  tumour classiﬁcation of 2007. Histological classifca-
ion of pilomoyxoid astrocytomas can be difﬁcult, particularly in
umours showing characteristics of both pilomxyoid and pilocytic
strocytomas (Johnson et al., 2010).
While PAs are commonly found in NF1-patients and usually
ollow an indolent course, pilomyxoid astrocytomas are less com-
only observed in the context of NF1 (Louis et al., 2007).
Pilomyxoid and diffuse astrocytomas are classiﬁed as grade II
umours and show more aggressive behaviour than PA, but still
orm a group of relatively slow progressive tumours. Diffuse astro-
ytomas are characterized by diffuse inﬁltration and cytological
typia, but no anaplasia or mitotic activity.ition of MDM2  activates p53 while p16 regulates the retinoblastoma (RB) protein.
vated in a TSC2-dependent way. The different inhibitors mentioned in the text and
PAs are most commonly found in children, predominantly in
ﬁve till nine year olds. In contrast, diffuse astrocytomas are more
common in the adult population with only 12% presenting before
the age of 20 (Rodriguez et al., 2008). A summary of the different
characteristics of the subtypes of paediatric low grade gliomas is
given in Table 1.
A comparison will be made between NF1 and non NF1-related
low grade gliomas at different anatomical locations. Because PAs
are the most common subtype of low grade gliomas in the paedi-
atric population, the focus will be on this histological subtype (see
also Table 2).
3.2. Location
PAs generally occur at places where piloid cells are normally
present in the central nervous system: along the ventricles, aque-
duct and central canal as well as in the optic nerve, chiasm and
optic tract. In the paediatric population, the cerebellum is the most
prevalent location. However in the context of NF1, PAs are most
often located in the optic pathway or brainstem. In the follow-
ing section a comparison between clinical details of NF1 and non
NF1-associated low grade gliomas is made, with a subdivision in
supratentorial and infratentorial locations.
3.2.1. Supratentorial low grade gliomas
Supratentorial low grade gliomas compromise a subgroup of
tumours, including tumours of the cerebral lobes and the basal
ganglia, which are only seldomly observed in NF1. However, optic
pathway gliomas are far more common, both in NF1 and sporadic
cases (Guillamo et al., 2003).
3.2.1.1. Optic pathway glioma. NF1-associated low grade gliomas
are most frequently found in the optic pathway, with a preva-
lence of 15–25% for optic pathway gliomas (OPGs) among NF1
patients. If tissue is obtained, most of these tumours are classiﬁed
as PA (Szudek et al., 2000; Hernaiz Driever et al., 2010; Guillamo
et al., 2003; Listernick et al., 2007; Czyzyk et al., 2003). Presenting
symptoms may  include ophthalmological abnormalities, such as
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Table  1
Characteristics of different subtypes of low grade gliomas occuring in children.
Pilocytic astrocytoma Pilomyxoid astrocytoma Diffuse astrocytoma
Histological features Biphasic histology with piloid cells and
more loosely arranged astrocytes.
Prominent myxoid matrix and
angiocentric arrangement of
monomorphous, piloid tumour cells.
Astrocytic cells with mild nuclear
atypia.
Incidence (per 100.000 per year) 0,48 Unknowna 0,14
Association with NF1 Mainly OPG (50%) Rare, case reportsa Rare
Age  5 to 19 years Median age 10 months Mean age 39.1
WHO  grade I II II
Mean  overall survival (months) 233 60 71.1
Mutations BRAF-fusions (mainly KIAA1549;BRAF
fusion), BRAF, NF1, FGFR1, NTRK2,
PTPN11
Unknowna BRAF, TP53, IDH1
Location Mainly cerebellum/Brainstem/Optic
pathway
Mainly hypothalamic/Chiasmic regions Brain parenchyma
a Partially due to inconclusive diagnoses of pilocytic or pilomyxoid astrocytoma GFAP: glial ﬁbrillary acid protein; OPG: optic pathway glioma (Louis et al., 2007; Sievert
and  Fisher, 2009; Komotar et al., 2004; Bourne and Schiff, 2010).
Table 2
Outlining the differences between NF1 and non NF1-associated low grade gliomas in the paediatric population in different locations.
Supratentorial
Optic pathway Other
NF1 Non NF1 NF1 Non NF1
Percentage of tumours >50% 10% 15% (Hernaiz Driever
et al., 2010; Guillamo
et al., 2003)
5–10%
Most  common genetic
alterations
NF1 gene mutation BRAF fusions; NTRK2
fusion
NF1 gene mutation –
Mean age at
presentation
4.6 years 4.8 years – –
Prognosis 5 y PFS of 71%
(Stokland et al., 2010)
5 y OS of 94% (Stokland
et al., 2010) b
– 5 y OS  of 92% (Stokland
et al., 2010) b
3 y PFS of 82% (Laithier
et al., 2003)
3 y PFS of 42% (Laithier
et  al., 2003)
10 y OS  of 95%
(Gnekow et al., 2012) b
5 y EFS of 19% (Hernaiz
Driever et al., 2010) a
10 y EFS of 63%
(Gnekow et al., 2012) b
Infratentorial
Cerebellar Brainstem
NF1 Non NF1 NF1 Non NF1
Percentage of tumours 4% 50% 17% 15%
Most  common genetic alterations. NF1 gene mutation KIAA1549:BRAF fusion NF1 gene mutation BRAF fusions,
BRAFv600E/, FGFR1
mutations
Mean  age at presentation – 7.9 years – 6.5 years
Prognosis – 5 y OS of 98% (Stokland
et al., 2010) b
– 5 y OS of 85% (Stokland
et al., 2010) b
10 y OS of 98%
(Gnekow et al., 2012) c
5 y PFS of 64%
(Stokland et al., 2010) b
– Indicates there is no or not sufﬁcient data available to draw any conclusions (Grimm and Chamberlain, 2013; Hayostek et al., 1993).
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aa This number includes only hypothalamic and chiasmatic tumours.
b No discrimination between NF1-positive and NF1-negative patients.
c No discrimination between NF1-positive and NF1-negative patients;this percen
trabismus, visual ﬁeld defects, decreased visual acuity, abnormal
upillary function, decreased colour function, optic nerve atro-
hy or proptosis as well as diencephalic syndrome and precocious
uberty, especially in chiasmatic tumours. A signiﬁcant percentage
f patients seem to remain asymptomatic; this may  be partially
aused by incomplete reporting of visual impairment in younger
hildren, due to a lack of adequate testing modalities (Listernick
t al., 2007).
Compared to non-NF1 associated OPGs, NF1- related OPGs may
ave a slightly earlier age of presentation, with a median age of 4.6
ersus 4.8 years in a group of 83 optic gliomas, but this difference
s not signiﬁcant over different studies.
There may  be a slight female preponderance in NF1-associated
PG, but this is not consistent over different studies. OPGs not
ssociated with NF1 show an equal sex distribution. Recently itncludes both cerebellar and brainstem tumours.
was shown that female patients with NF1-associated OPG are more
prone to become symptomatic and three times more likely require
treatment (Fisher et al., 2014; Diggs-Andrews et al., 2014). Multi-
focal distribution, optic nerve involvement and bilateral gliomas
occur more often in NF1, while chiasmal location, extra-optic
growth and cystic morphology are more common in sporadic OPGs
(Czyzyk et al., 2003; Listernick et al., 1995; Shamji and Benoit,
2007).
The classical Dodge staging system for OPGs classiﬁes tumours
based on anatomy with involvement of either the optic nerves,
the optic chiasm and the hypothalamus with associated structures
(Dodge et al., 1958). Based on MR  image sequences, a modiﬁed
Dodge classiﬁcation has been developed which permits a more
detailed description of tumour involvement at multiple anatom-
ical locations in the optic pathway area. In NF1-positive tumours,
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his method revealed a tendency towards an asymmetrical involve-
ent at the optic chiasm, whereas NF1-negative tumours tend to
ocalize more centrally at the chiasm (Taylor et al., 2008). The capac-
ty of the modiﬁed Dodge classiﬁcation to discriminate central and
symmetrical localization at the chiasm has great value in predict-
ng visual outcome before and after OPG treatment. In line with this,
ostchiasmatic localization of NF1-positive OPGs was  found to be
orrelated with worse visual outcome compared to other anatomi-
al locations in the optic pathway area (Fisher et al., 2012). A recent
ultidisciplinary consensus proposed to (Taylor et al., 2008) revise
he modiﬁed Dodge classiﬁcation system for OPGs by addition of
urgical and clinical factors, in order to assist standardized surgical
ssessment of tumours in the optic pathway area (Walker et al.,
013).
Progression rates of OPGs are usually slow, especially in the con-
ext of NF1. In a group of 83 OPGs, radiologic progression rates were
igher in sporadic OPG (40%) even after treatment, compared to 28%
n untreated NF-1 related OPG (Czyzyk et al., 2003). Spontaneous
egression has been described as a typical feature of NF1- related
PG, but may  occur in both NF1- and sporadic OPG (Liu et al., 2013).
In accordance with the slow progression rates, overall survival
s generally good. In very young children (<1 year old), sporadic
PGs are associated with poorer overall survival, which is related
o tumour location and the occurence of diencephalic syndrome
Stokland et al., 2010; Laithier et al., 2003; Gnekow et al., 2012,
004; Opocher et al., 2006). While survival rates are high, the most
mportant concern in OPGs is loss of visual function. Vision loss
ccurs in children with NF1-associated OPG at any age, with a
edian age between 3 and 5 years. In younger children rates of
ision loss may  be underestimated due to difﬁculties in assessing
isIon loss in this population (Listernick et al., 2007; Fisher et al.,
012).
While the main reason to initiate treatment in OPG is loss of
isual function, effects of treatment on visual function are variable
s was shown in different non-randomized trials (Moreno et al.,
010). In a large cohort of 115 children with NF1-associated OPG,
ision improved (32%), remained stable (40%) or worsened (28%)
fter chemotherapeutic treatment (Fisher et al., 2012).
Interestingly, a poor correlation between radiographic and
isual outcome was described. Furthermore a correlation between
umour location and outcome after treatment was  found, with
umours involving the optic tract or its radiations associated
ith worse visual outcome and increased mortality. Therefore a
wait and see” approach is suggested for prechiasmatic tumours
xhibiting radiographic progression without apparent risk of visual
oss, while a more aggressive treatment approach is advocated in
post)chiasmatic tumours, which pose a higher risk of visual loss
Sievert et al., 2013). Together these studies state the importance
f regular radiographic, but maybe more important, ophthalmo-
ogic follow-up in NF1-associated OPGs (Opocher et al., 2006).
phthalmologic screening should focus on visual acuity, by includ-
ng speciﬁc quantitative measuring methods as visual endpoints
“Teller acuity cards” and “Snellen”, or “HOTV”), and the assessment
f optic disc pallor (Fisher et al., 2013).
.2.2. Infratentorial low grade gliomas
Infratentorial low grade gliomas, mainly classiﬁed as PA, include
esions of the cerebellum, brainstem and spinal cord. Spinal cord
As are rare tumours, both in NF1 and non-NF1 patients, while
rainstem low grade gliomas are more often seen. The cerebellum
s the most common location for non-NF1 associated PAs but is a
are location for NF1-associated tumours..2.2.1. Cerebellum. Tumours of the posterior fossa probably rep-
esent only approximately 4% of central nervous system tumours
n NF1 (Rodriguez et al., 2008). In a cohort of 600 NF1 patients inlogy/Hematology 104 (2016) 30–41
Spain followed for 39 years, only 4 developed grade I astrocytomas
involving the posterior fossa, while only one of those had a primary
origin in the cerebellum (Pascual-Castroviejo et al., 2010). Cere-
bellar lesions in NF1 are believed to have a less favourable natural
course than optic pathway gliomas with aggressive resection being
the ﬁrst choice of treatment (Pollack and Mulvihill, 1996). While
rare in the context of NF1, the cerebellum is the most common
location for sporadic pilocytic astrocytomas (Louis et al., 2007).
3.2.2.2. Brainstem. In a cohort of 104 patients with NF1 and a cen-
tral nervous system tumour, the brainstem was  the second most
common location of brain tumours, representing 17% of all and 49%
of patients with an extra-optic tumour. Extra-optic tumour loca-
tion was  associated with a less favourable prognosis in this cohort
(Guillamo et al., 2003). However in NF1, like optic pathway gliomas,
brainstem lesions are most often asymptomatic and only show a
low frequency of clinical progression with a more favourable prog-
nosis than non NF1-associated brainstem gliomas (Pollack et al.,
1996). Because of their relatively indolent behaviour and the high
risk of invasive biopsy or resection, these procedures are seldom
performed and a histologic diagnosis is therefore rarely made. A
retrospective study from the Mayo-clinic on 48 resected low grade
brainstem gliomas in children indicated that most of these tumours
are astrocytomas, predominantly pilocytic astrocytomas, but the
NF1 status of the children is not mentioned in this article (Ahmed
et al., 2014).
3.2.3. Comparison of supratentorial and infratentorial lesions
PAs from different brain regions, both with and without an
association with NF1 are histologically mostly similar. However,
the age of presentation,progression free survival and overall sur-
vival depend on PA location, which is mostly due to resectability
of the tumour (Stokland et al., 2010). Furthermore different gene
expression proﬁles related to PA location have been found, such as
supratentorial and infratentorial PAs (Belirgen et al., 2012).
Throughout these different gene expression proﬁles,the only
gene consistently showing increased expressionin supratento-
rial tumours compared to infratentorial tumours is LHX2. In the
forebrain of zebraﬁsh, thisgene is involved in cellular prolifer-
ation through SIX3 (Sharif et al., 2011; Mascelli et al., 2013;
Tchoghandjian et al., 2009; Ando et al., 2005). LHX2 is believed to
be an important regulator of embryonic development. It functions
as a suppressor of embryogenic astrogliogenesis during the neu-
rogenic period and is involved in maintaining optic identity in the
optic vesicle (Subramanian et al., 2011; Roy et al., 2013). However,
its role in human brain tumors remains elusive and LHX2 expres-
sion in suptratentorial tumours seems to be unrelated to the NF-1
status of the patient (Sharma et al., 2007).
The observed difference in gene expression proﬁles between
infratentorial and supratentorial tumours suggests a relation
between tumourigenesis and tumour location. Recently, a whole
genome sequencing study carried out by the international genome
consortium pedbrain tumour project underlined this statement by
revealing that different mutations found in PA may  be brain region-
speciﬁc, as will be further discussed below (Jones et al., 2013).
3.3. Tumourigenesis
Whereas NF1- associated PAs are histologically similar to spo-
radic PAs, the oncogenic molecular mechanisms underlying these
tumours are different, which translates into differential localisa-
tion patternsand clinical behaviour. Over the past few years an
increased insight into mechanisms involved in tumourigenesis in
both sporadic and NF1-related PAs has helped in the understanding
of these differences.
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.3.1. NF1-associated pilocytic astrocytomas
As in other NF1-related malignancies, loss of NF1 gene expres-
ion and neuroﬁbromin expression has been shown in NF1-related
As. This suggests a second hit mechanism, in which somatic inac-
ivation of the still functioning NF1 allele is required for tumour
ormation (Gutmann et al., 2000, 2003; Kluwe et al., 2001). Different
echanisms, including frameshift mutation, loss of heterozygos-
ty and methylation are known to be responsible for the somatic
nactivation of the NF1 gene in human PAs (Gutmann et al., 2013).
Further evidence for this second hit mechanism came from
ouse models of NF1. First, mice heterozygous for NF1 show
ncreased astrocyte growth in the brain, dependent of neu-
oﬁbromin. However, these mice do not develop astrocytomas
Gutmann et al., 1999). Second, transgenic mice with a NF1 con-
itional knockout speciﬁc to astrocytes do also show astrocytosis
ndependent of the timing of the knockout, but do not exhibit
strocytoma formation (Bajenaru et al., 2002). Thus, loss of neu-
oﬁbromin function in astrocytes is not sufﬁcient for astrocytoma
ormation.
Third, an astrocyte-speciﬁc knockout of NF1 was performed in
ice heterozygous for NF1. All of these mice developed lesions
imilar to optic gliomas in humans (Bajenaru et al., 2003, 2005).
These experiments do not only underline the importance of
omplete inactivation of NF1 in optic glioma formation, but also
how the importance of a proper tumour environment for glioma-
enesis.
This provides a model for tumourigenesis in NF1, but it does
ot explain the localisation of NF1-associated astrocytomas along
he optic pathway, the cerebellum or in the brainstem. One possi-
le explanation for this localisation pattern has been found in the
ouse model of NF1 associated PAs, which is a brain region-speciﬁc
ffect of NF1 gene inactivation. This is shown by increased prolif-
ration in cerebellar, brainstem and optic pathway astroglial cells
ut not cortical astroglial cells after NF1 inactivation, as well as the
igher proliferation of neural stem cells in the brainstem but not in
he cortex after NF1 loss (Yeh et al., 2009; Lee da et al., 2010).
This brain region-speciﬁc effect is further supported by the for-
ation of optic pathway gliomas after NF1 inactivation in neural
tem cells of the subventricular zone of the third ventricle during
mbryogenesis, but not of the lateral ventricles (Lee da et al., 2012).
The effects of NF1 inactivation are not only brain region- and
ell-speciﬁc, but may  also be subject to adequate timing, providing
 possible explanation for the almost exclusive presentation of PAs
n children. This is suggested by characteristics of progenitor cells in
he OPGs in the previously described NF1 mouse model and the fact
hat no glioma formation is seen when NF1 knockout is performed
n adult astrocytes (Bajenaru et al., 2005; Zhu et al., 2005b).
While these mice models have greatly increased the under-
tanding of gliomagenesis and provided some answers to the brain
egion- and timing-speciﬁc occurrence of gliomas in NF1, it is still
uestionable which children with NF1 are prone to optic glioma for-
ation. A molecular analysis of NF1 mutations in 80 patients with
F1 and an OPG found clustering of mutations at the 5′ end of the
F1 gene in patients with OPG as a possible genotype-phenotype
ssociation (Sharif et al., 2011).
A recently emerging factor in tumour formation is the role of
icroRNAs. These are small non coding RNA-particles, that inhibit
ranscription through binding of the RNA-strand, and can act both
s a proto-oncogene and as a tumour suppressor gene. They show
lterations in paediatric PAs in general and are believed to be
nvolved in the development of MPNSTs in NF1 (Esparza-Garrido
t al., 2013; Sedani et al., 2012). Their role in NF1-associated PAs is
ot known yet, but these studies indicate they might be involved
n tumour formation and susceptibility.logy/Hematology 104 (2016) 30–41 35
Another important factor in susceptibility to glioma formation
may  be the genetic background, as was shown in a murine model.
In this model, mice mutated for NF1 and Tp53 only developed
glioblastomas on a certain genetic background (B6), while mice
with these mutations on a 129-background are highly resistant to
tumour formation (Reilly et al., 2004, 2000). Further explanations
for the susceptibility to glioma formation in about 20 percent of
children remain to be found.
3.3.2. Comparison with sporadic PA
While NF1 loss is required for formation of PA, NF1 loss is
not found in sporadic PA, suggesting another driving mechanism
behind tumour formation (Kluwe et al., 2001; Wimmer et al., 2002).
In contrast, the majority of non-NF1-associated PA show an activa-
tion of BRAF, caused by fusion of BRAF with KIAA1549, due to a
duplication at 7q34 (Jones et al., 2008). This BRAF alteration is not
found in glioblastoma or ependymoma, indicating that it is speciﬁc
for PA.
Other genetic alterations in sporadic PAs include BRAFins598T
and BRAFV600E mutations, the latter being common in human
melanomas, and fusion between SRGAP3 and RAF1 (Jones et al.,
2009). Mutations in p53 are only sporadically found in paediatric
PAs. One study reported a frequency of 35 percent, but this number
has not been conﬁrmed in further studies (Hayes et al., 1999).
The recently published whole genome sequencing study on 96
PAs identiﬁed BRAF fusions in 76 of 96 PAs. In correspondence
with previous ﬁndings, the KIAA1549:BRAF fusion was the most
frequently found alteration. Furthermore two new NTRK2-fusions
were described and new mutations were identiﬁed within the
kinase domain of FGFR 1 and in the phosphatase gene PTPN11.
Interestingly all of these new mutations were found in non-
cerebellar tumours, possibly indicating a link between mutation
and the brain region of tumour formation. The results of this study
are summarized in Fig. 2 (Jones et al., 2013).
In vitro, cerebellar neural stem cells transduced with the
KIAA1549:BRAF fusion show increased cell growth. After injection
of these cerebellar neural stem cells in mouse cerebella, these mice
develop glioma-like lesions after 6 months. Because this effect is
not seen in cortical neural stem cells nor in astrocytes, this is in
concordance with a brain region- and cell-speciﬁc response to the
KIAA1549:BRAF fusion, comparable with that seen in NF1 (Kaul
et al., 2012, 2013).
3.4. Signalling pathways
While the mechanism behind increased Ras/Raf signalling is
different in NF1-associated and sporadic PAs, there are similar
consequences of the activation of this pathway, possibly explain-
ing the common histological properties of these tumours (Fig. 1).
Because both sporadic and NF1-associated PAs show activation of
the mTOR-pathway and MAPK pathway and these pathways pro-
vide possible targets to molecular therapy, we will focus on these
pathways (Jones et al., 2013; Kaul et al., 2012; Forshew et al., 2009).
3.4.1. MAPK-pathway
MAPK signalling is activated in most, if not all PAs with differ-
ent mechanisms responsible for its activation (Jones et al., 2013,
2008; Forshew et al., 2009). In NF1 related PAs, the MAPK pathway
is activated through increased RAS-signalling after unrestrained
phosphorylation of RAS through absence of neuroﬁbromin (Lau
et al., 2000). Although the downstream effects of MAPK activation
in NF1 associated PA are not completely understood, inhibition of
this pathway may  be a potential target for treatment. In vitro and
mouse models of NF1-associated MPNSTs and neuroﬁbromas show
efﬁcacy of MAPK inhibition (Jessen et al., 2013). Furthermore, MAPK
inhibition is effective in rescuing brain abnormalities in mice with
36 J. Helfferich et al. / Critical Reviews in Oncology/Hematology 104 (2016) 30–41
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(ig. 2. Genetic alterations in paediatric astrocytomas as was  found in the whole g
ay  be caused by limited tissue obtained from this group of patients (Jones et al., 2
iallelic inactivation of NF1 neural stem cells, with normalization
f MAPK levels (Wang et al., 2012).
In sporadic PA different genetic alterations are responsible for
APK activation, including BRAF fusions and FGFR1 mutations
Jones et al., 2013, 2009). In vitro experiments show diminished
roliferation after MAPK inhibition in cell lines harbouring these
ene alterations (Kaul et al., 2012; Zhang et al., 2013). The general
ctivation of MAPK has led to clinical trials targeting this pathway
n paediatric PA.
.4.2. mTOR-pathway
The mTOR pathway is a critical pathway in cell survival, cell
rowth and proliferation. Anologous to the MAPK-pathway, it has
hown to be a potent driver of tumourigenesis (Zoncu et al., 2011).
In humans, the mTOR-pathway is hyperactivated in NF1-
ssociated PAs, as is shown by increased levels of phosphorylated
6 (Lau et al., 2000; Dasgupta et al., 2005a). This mTOR hyperactiva-
ion is also seen in the mouse model of NF1 OPG, with higher levels
f S6 in OPG tissue of genetically engineered NF+/− mice, compared
o tissue of the optic chiasm of control mice (Dasgupta et al., 2005a).
The exact mechanism of mTOR-activation in NF1 associated
As remains to be revealed, but some evidence comes from the
ouse model of NF1 OPG. In this mouse model, inhibition of
TOR with rapamycin is effective in decreasing tumour cell pro-
iferation in a dose dependent matter (Hegedus et al., 2008).
apamycin crosses the blood brain barrier and shows an exponen-
ial increase of brain levels as a response to increase of dosage,
ossibly indicating a threshold function of blood- brain barrier
roteins. Interestingly, the growth inhibiting effects of rapamycin
eem not to be fully reﬂected by S6- or Akt-phosphorylation, since
 lower concentration of rapamycin was required for inhibition of
6- or Akt-phosphorylation than for maximal growth suppression
Banerjee et al., 2011b).
Further attempts on eludicating the mechanism by which
TOR regulates astrocyte proliferation were made in-vitro stud-
es. It was shown that the mechanism by which neuroﬁbromin
egulates mTOR and controls cell growth is Akt-dependent but
SC-independent (Banerjee et al., 2011a; Johannessen et al., 2005).
Non-NF1 associated astrocytomas carrying the KIAA1549:BRAF
usion also show increased mTOR activation. In cerebellar neural
tem cell lines carrying the fusion, this mTOR-pathway activation
as shown to be through MEK-dependent TSC2 inactivation (Fig. 1)
Kaul et al., 2012). sequencing study. An underestimation of the number of NF1 associated tumours
While different mechanisms are responsible for mTOR-
activation in NF1 and non NF1-associated PAs the common
activation of this pathway and preclinical results, have led to clini-
cal trials with different mTOR-inhibitors in paediatric PA, of which
results are pending.
3.5. Tumour micro-environment
Inactivation of the NF1 gene in astroglial cells is only sufﬁ-
cient for gliomagenesis in a context of heterozygous NF+/− mice
and shows brain region- and cell-speciﬁc effects (Bajenaru et al.,
2002, 2003). This creates the idea in which inactivation of the NF1
gene is only sufﬁcient for gliomagenesis in a proper tumour micro-
environment, or in which NF1 gene loss can only occur in a speciﬁc
environment.
In correspondence with these theories, there is a relatively high
proportion of stromal cells in the PAs in NF1 (Gutmann et al., 2013).
Different studies have focused on the role of NF+/− stromal cells
in promoting tumour formation, for example by examining cAMP
(Warrington et al., 2007) -signalling in stromal cells. The chemokine
CXCL12 functions as a suppressor of cAMP levels after binding its
receptor CXCR4 and is highly expressed in the optic pathway of
young children.
Similar to the human situation, CXCL12- expression is high in the
optic pathway of young mice, and cAMP levels are high in the cortex
but not in the optic pathway. In vitro, increased CXCL12-expression
suppresses c-AMP signalling and causes increased survival of NF1-
gene knockout astrocytes (Warrington et al., 2007). Decreased
stromal cAMP expression promotes gliomagenesis in mice het-
erozygous for NF1. Gliomas, similar to the mouse OPGs, form in the
cortex of these mice after inhibition of cAMP-expression. Glioma
growth was inhibited by reversing this effect through re-increasing
cAMP levels (Warrington et al., 2010).
Together these ﬁndings underline the role of paracrine sig-
nalling by the tumour microenvironment and in particular cAMP in
NF1 OPGs. Furthermore they contribute to the explanation of the
spatial pattern of gliomagenesis in NF1 (Warrington et al., 2007,
2010).
Other stromal inﬂuences may  come from increased c-Jun-Nh2-
kinase (JNK) sigaling, hyaluronidase production and the expression
of chemokine receptor CX3CR1. Cultured microglia from heterozy-
gous NF+/− mice show increased JNK signalling and inhibition of this
signalling is associated with decreased proliferation both in vitro
and in vivo (Daginakatte et al., 2008). Hyaluronidase is a paracrine
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actor produced by NF1 heterozygous microglia and increases
strocyte proliferation through MAPK-signalling. Its inhibition is
ssociated with decreased growth of NF1 knockout astrocytes
Daginakatte and Gutmann, 2007).
The chemokine receptor CX3CR1 is involved in signalling in the
entral nervous system and is also highly expressed in NF1 OPG
icroglia. Reduced expression of this receptor is associated with
elayed optic glioma formation in mice heterozygous for NF1 (Pong
t al., 2013).
Altogether, there seems to be an important role for the tumour
icroenvironment in NF1 glioma growth. However, the mecha-
ism by which the microenvironment regulates tumour growth
as to be further clariﬁed. Better insights into this mechanisms may
ive way to the development of intelligent therapy targeting both
umour and microenvironment.
It remains to be revealed what the role of tumour micro-
nvironment is in tumour formation in non NF1-associated PAs.
he brain region-speciﬁc effects of the KIAA1549:BRAF fusion in
ouse models suggest that tumour-environmental inﬂuences may
lso play a role in these tumours (Kaul et al., 2013).
.6. Angiogenesis
Angiogenesis is critically involved in tumour growth in high
rade gliomas, which has led to preclinical and clinical trials of
nti-angiogenic therapy (Dunn et al., 2012). PAs, like high grade
liomas, are highly vascular, suggesting that targeting vascularisa-
ion or angiogenesis may  also be a treatment option in PA.
A comparison of vasculature of paediatric PA with adult glioblas-
oma revealed that there are less vessels in PA, but these vessels are
ider than those in glioblastoma. The lower number of vessels cor-
elated with higher VEGF-A expression, possibly indicating VEGF
s a target for therapy. Vessel maturity, described as the balance
etween ANGPT1 and ANGPT2, was higher in the whole group of PA.
nterestingly the cerebellar PA showed less vessel maturity, even
omparable with that of glioblastoma, while showing the widest
essels (Sie et al., 2010).
It has been shown that increased microvessel density is associ-
ted with shorter survival in gliomas (Leon et al., 1996). For low
rade gliomas, higher microvessel density was associated with
ower progression free survival in a study in 41 children with
ncompletely resected tumours of the optic pathway and hypotha-
amus.
Results were similar between NF1-associated and sporadic
PGs, suggesting that this vascularisation pattern is preserved in
F1-associated PAs. However these results may  be biased by the
election of a group of NF1 associated OPGs that were eligible
or surgery (Bartels et al., 2006). The highly vascular pattern and
ndothelial hyperplasia of OPGs in the mouse model of NF1 is in
ine with a comparable vascular pattern in NF1 associated gliomas
Bajenaru et al., 2005; Kim et al., 2010).
The mechanism by which increased vascularity in NF1 related
umours is attained is not completely clear but may  be associated
ith NF1 gene loss or downstream activation of different path-
ays. NF1 is associated with vascular pathology, possibly involving
ll blood vessels (Rosser et al., 2005). Although the exact mecha-
ism behind this vasculopathy remains unclear, neuroﬁbromin is
idely expressed in blood vessels, suggesting a possible role for
F1 signalling in NF1 vasculopathy (Rodrigues et al., 2013). NF1
ignalling might have a role in pericyte and endothelial prolifera-
ion and recent studies in Schwann cell lines suggest that activation
f mTOR and VEGF after NF1 loss may  be involved in vascularisation
Ozerdem, 2004; Kawachi et al., 2013).
Only limited information on clinical use of angiogenic inhibitors
n paediatric low grade gliomas is available, but studies in high
rade gliomas in both children and adults have shown varyinglogy/Hematology 104 (2016) 30–41 37
results. (Reviewed in (Dasgupta and Haas-Kogan, 2013)) Effects of
anti-angiogenic treatment in PAs in both NF1 and non-NF1 associ-
ated tumours remain to be determined.
4. Treatment
Survival rates of low grade gliomas, especially PAs, are excellent
after treatment and exceed 90 procent after ﬁve and ten years in dif-
ferent studies (Louis et al., 2007; Stokland et al., 2010; Gnekow et al.,
2012). Current treatment options for low grade gliomas in children
include surgery, radiotherapy and chemotherapy or a combination
of these modalities, as well as BRAF-inhibitors in speciﬁc tumours
(Walker et al., 2013).
If the tumour is accessible for resection without considerable
adverse damage, this is usually the mainstay of treatment as
complete resection is associated with better rates of overall and
progression free survival. Ten year overall survival rates of 99% vs.
94% and progressive free survival rates of 85% vs. 48% for total vs.
subtotal resection were found in one large study, with comparable
numbers in a second. (ﬁve year overall and progressive free survival
of 99% vs. 90% and 94% vs. 49% respectively) (Stokland et al., 2010;
Gnekow et al., 2012).
As for optic pathway tumours a multidisciplinary consensus
stated that resection is usually not the ﬁrst choice of treatment,
because of the generally less aggressive behaviour, especially in the
context of NF1, as well as the location hampering total resection.
A multidisciplinary approach should be taken to decide timing and
form of treatment, taking into account visual function and tumour
progression. Both before treatment is initiated and after treatment
is started, regular radiographic and ophthalmologic follow up is
warranted (Hernaiz Driever et al., 2010; Fisher et al., 2012; Walker
et al., 2013).
Chemotherapy is now considered as ﬁrst choice adjuvant ther-
apy in low grade gliomas, with different regimens, including a
combination of carboplatin and vincristine being effective in con-
trolling progressive disease, independent of NF1-status (Packer
et al., 1997).
Furthermore this treatment regimen has shown to reach pro-
gression free survival rates of 73 percent as a primary treatment
in NF1 patients (Hernaiz Driever et al., 2010). As mentioned, a
major concern in low grade gliomas in NF1 located along the optic
pathway is visual outcome. Effects of treatment on visual outcome
are variable over different studies (Moreno et al., 2010). A study
analysing visual outcome in NF1 patients after chemotherapeutic
treatment showed stabilisation or improvement of visual acuity
after treatment with chemotherapy in most cases, while a decline
of visual acuity is still seen in 28 percent of children after treatment.
A location along the optic tract or optic radiation is associated with
worse visual outcome (Fisher et al., 2012). In a more recent study
stability was also the most common outcome after treatment for
OPGs in general, where younger age and chiasmatic/hypothalamic
tumours were associated with worse visual outcome (Dodgshun
et al., 2015). Furthermore, for reasons not yet known, female gen-
der seems to be associated with a higher risk of requiring treatment
(Fisher et al., 2014; Diggs-Andrews et al., 2014).
A trial comparing carboplatin and vincristine with a combina-
tion of thioguanine, procarbazine, lomustine, and vincristine in 274
children showed no signiﬁcant difference between these treatment
regimens, suggesting this may  be an alternative depending on tox-
icity (Ater et al., 2012).
Other chemotherapeutics studied in low grade gliomas include
temozolomide, vinblastine and etoposide, where a combination
of cisplatin and etoposide may  be effective instabilising disease
(Massimino et al., 2002; Bouffet et al., 2012; Gururangan et al.,
2007). However, unpublished results of the SIOP LGG 2004 study,
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n international cohort study comparing standard therapy (carbo-
latin and vincristine) with carboplatin/vincristine and etoposide
nduction therapy show no advantage of the latter.
Radiotherapy is, because of its side-effects, not considered a
rst line treatment in pediatric low grade gliomas, especially not in
ounger children. It can however be an effective treatment form for
ow grade gliomas, both in patients with and without NF1 (Hernaiz
riever et al., 2010; Stokland et al., 2010; Merchant et al., 2009).
n a subgroup analysis of the HIT LGG 1996 cohort both stereo-
actic brachytherapy and external fractioned radiotherapy were
hown to be effective in controlling tumour progression in older
hildren. Long-term functional outcome was not reported in this
tudy, whereas long-term side effects may  be more common after
adiotherapy, especially in younger children (Gnekow et al., 2012;
uller et al., 2013).
In NF1 patients, radiotherapy has been associated with
he occurrence of secondary brain tumours and vasculopathy
Merchant et al., 2009; Grill et al., 1999; Sharif et al., 2006). Proton
eam therapy may  provide an alternative to conventional radio-
herapy, with radiation better targeted to the tumour site. One
tudy performing proton therapy in 27 children with low grade
liomas showed promising results, with a high efﬁcacy particularly
n centrally localised tumors. Short term side effects were limited in
mall series, but included the development of Moyamoya disease in
 patient with NF1. Further research on long-term side effects and
fﬁcacy are now on their way (Hug et al., 2002; Hauswald et al.,
012).
In summary, results of current treatment options in terms of
verall survival and progression free survival are generally good,
specially if total resection can be reached. However, particularly in
hildren younger than one and in supratentorial midline tumours,
igher rates of progression free survival are needed (Gnekow et al.,
012). Precision medicine, targeting the above mentioned path-
ays may  provide a valuable alternative to the current treatment
ptions (Terashima et al., 2013).
The presence of BRAF alterations in a major proportion of non
F1- associated PAs has led to an experiment in which vemu-
afenib, a potent inhibitor of BRAFV600E in melanoma cells, was tried
n cell lines carrying a stable BRAF:KIAA1549 fusion. Paradoxal
APK activation and mTOR activation in these cell lines suggest
hat ﬁrst line anti-BRAF treatment is not effective. However, sec-
ndary BRAF-inhibitors, such as PLX PB-3 are more effective in
hese cell lines in inhibiting mTOR and cellular proliferation (Sievert
t al., 2013). A ﬁrst phase II clinical trial with sorafenib, an inhibitor
argetting BRAF, VEGFR, PDGFR and c-kit was terminated because
f an unexpected acceleration of tumour growth, which was  not
ependent on NF1 status (Karajannis et al., 2014).
While BRAF inhibition may  only be effective in sporadic PAs,
AS activation is a feature of both NF1-related and some sporadic
As, indicating a possible role for RAS-inhibition in PA (Sharma
t al., 2005). Farnestyltransferase inhibitors, which inhibit RAS by
nteracting with the insertion of RAS in the plasma membrane,
ave however not shown to be effective in the treatment of NF1-
ssociated plexiform neuroﬁbromas. The authors suggest a K-RAS
peciﬁc regulation by NF1 as a possible explanation for this inef-
ectiveness (Widemann et al., 2006; Dasgupta et al., 2005b).
Further downstream, promising targets for therapeutic inter-
ention include the MAPK-pathway and the mTOR-pathway,
ith clinical trials targeting these pathways being underway. In
ig. 1, the above mentioned agents and their point of action are
hown. In addition, new therapies may  target the tumour micro-
nvironment, including activation of cAMP-signalling or inhibition
f angiogenesis.
As PAs are highly vascular tumours, anti-angiogenic agents
re interesting candidates in novel treatment approaches and one
f the mostly evaluated drugs is the monoclonal antibody beva-logy/Hematology 104 (2016) 30–41
cizumab, which targets all the isoforms of the vascular endothelial
growth factor A (VEGF-A). In children with recurrent low-grade
gliomas treated with bevacizumab in conjunction with the topoiso-
merase I inhibitor irinotecan, 6-month and 2-year PFS-rates were
85% and 48% respectively (Gururangan et al., 2014). A retrospec-
tive study with 16 children suffering from refractory or progressive
low-grade gliomas, showed that a similar treatment approach lead
to clinical improvement (44%) or stable disease (50%) (Kalra et al.,
2015). In general, in pediatric low-grade glioma patients with NF1-
associated and NF1-unassociated tumours, the mean therapeutic
response to treatment with bevacizumab alone, or in conjugation
with irinotecan, shows high variation across studies and the mean
effect of bevacizumab on 2-year progression-free survival was  not
better than conventional treatment strategies (Kilday et al., 2014).
5. Conclusions
Neuroﬁbromatosis type 1 is a tumour predisposition syndrome
with a particular association with low grade gliomas in the pae-
diatric population. These low grade gliomas, typically pilocytic
astrocytomas, have a better prognosis and show a different locali-
sation pattern than their sporadic counterparts, with a preferential
location in the optic pathway. Although many is known about these
low grade gliomas, a question unanswered is which children with
NF1 are prone to low grade glioma formation and which are not.
Over the past years the knowledge of mechanisms behind the
differences between NF1-associated and sporadic LGG, as well as
those behind tumourigenesis, have greatly increased, particularly
through different murine models. Different signalling pathways,
including the MAPK- and mTOR-pathway, now have a well estab-
lished role in PA. Other important players in gliomagenesis in NF1
are found in the tumour microenvironment and include angiogen-
esis and the production of different growth factors by stroma cells.
Although outcome of treatment in terms of overall survival
and progression free survival is generally good, there is still room
for improvement, paricularly in saving vision in optic pathway
gliomas. Much has been achieved improving survival using surgery,
radiotherapy and different regimens chemotherapy, but toxicity
and side effects of these treatments urge the search for alterna-
tive treatments, with precision medicine coming up a promising
alternative.
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